Therapeutic decision making in stages III and IV head and neck squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 129, Issue 1, 2003, Pages 26-35

  Gleich, Lyon L ^a   Collins, C Michael ^a   Gartside, Peter S ^a   Gluckman, Jack L ^a   Barrett, William L ^a   Wilson, Keith M ^a   Biddinger, Paul W ^a   Redmond, Kevin P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DECISION MAKING; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; KAPLAN MEIER METHOD; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NECK DISSECTION; OROPHARYNX CANCER; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PROSPECTIVE STUDY; RACE; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0037225124     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.129.1.26     Document Type: Article

References (14)

1. Harwood AR, Hawkins NV, Beale FA, Rider WD, Bryce DP. Management of advanced glottic cancer: a 10 year review of the Toronto experience. Int J Radiat Oncol Biol Phys. 1979;5:899-904.
2. Harwood AR, Beale FA, Cummings BJ, et al. Supraglottic laryngeal carcinoma: an analysis of dose-time-volume factors in 410 patients. Int J Radiat Oncol Biol Phys. 1983;9:311-319.
3. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
4. Pignon JP, Bourhis J, Domenge C, Designe L, for the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949-955.
5. Forastiere AA, Berkey B, Maor M, et al. Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone: Intergroup Trial R91-11 [abstract]. Proc Am Soc Clin Oncol. 2001;20:2A. Abstract 4.
6. Gibaldi M, Sulilivan S. Intention-to-treat analysis in randomized trials: who gets counted? J Clin Pharmacol. 1997;37:667-672.
7. Forastiere AA, Pfister DG, Ang K, et al. NCCN practice guidelines for head and neck cancers. Oncology. 2000;14:163-194.
8. Hoffman HA, Karnell LH, Funk GF, Robinson RA, Menck HR. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124:951-962.
9. List MA, Stracks J, Colango L, et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol. 2000;18:877-884.
10. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000;110:593-602.
11. Mendenhall WM, Amdur RJ, Stringer SP, Villaret DB, Cassisi NJ. Radiation therapy for squamous cell carcinoma of the tonsillar region: a preferred alternative to surgery? J Clin Oncol. 2000;18:2219-2225.
12. McDonough EM, Boyd JH, Varvares MA, Maves MD. Relationship between psychological status and compliance in a sample of patients treated for cancer of the head and neck. Head Neck. 1996;18:269-276.
13. Adelstein DJ, Adams GL, Li Y, et al. INT 0126: an intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell cancer. In: Programs and abstracts of the Fifth International Conference on Head and Neck Cancer; July 31, 2000; San Francisco, Calif. Abstract 161.
14. Strasser MD, Gleich LL, Miller MA, Saavedra HI, Gluckman JL. Management implications of evaluating the N2 and N3 neck after organ preservation therapy. Laryngoscope. 1999;109:1776-1780.